Semba BioSciences, a Madison, Wisconsin, company that makes devices geared toward purifying the increasing number of protein-based drugs on the market, has raised almost $1 million, according to regulatory filings.
The company said in June it expected to make $1 million this year, and would raise $750,000 to put toward sales and marketing of its Octave Chromatography System. The company raised $875,000, according to a recent regulatory filing.
Semba launched Octave in March. The device provides researchers screening and purification processes that Semba says are much more efficient than other methods.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company also offers small molecule separation and bioseparation products.
It had previously raised $2.5 million.
